Humulin Regular

Humulin Regular is a recombinant human insulin (Insulin human, rDNA) supplied as an injectable solution for subcutaneous or intravenous administration. It is marketed in the European Union and is available only by prescription. The product contains a standard strength of insulin, though specific unit concentration may vary by formulation. Humulin Regular is used to replace or supplement endogenous insulin in patients with diabetes mellitus and to help achieve glycemic control.

Humulin Regular is indicated for the management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus, as basal or mealtime insulin replacement. - Type 2 diabetes mellitus, when oral agents are insufficient to maintain target glucose levels. - Gestational diabetes, under specialist supervision, to control hyperglycemia. - Hospitalized patients requiring rapid‑acting insulin via intravenous infusion for surgical or critical care settings. - Use in pediatric patients when individualized dosing is required.

Like all insulin preparations, Humulin Regular may cause adverse reactions, most of which are related to its glucose‑lowering effect or injection site.

Common: - Hypoglycemia (low blood glucose), presenting with sweating, tremor, hunger, or confusion. - Injection‑site reactions such as redness, swelling, or mild pain. - Lipodystrophy, including lipohypertrophy at repeated injection sites.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions ranging from urticaria to anaphylaxis. - Edema or fluid retention, especially in patients with cardiac or renal impairment.

Healthcare providers should assess individual risk factors before initiating Humulin Regular and monitor patients regularly during therapy.

- Avoid use in patients with known hypersensitivity to recombinant human insulin or any excipients. - Adjust dose in renal or hepatic impairment, as insulin clearance may be reduced. - Caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Monitor for signs of hypoglycemia, especially when combined with other glucose‑lowering agents. - Educate patients on proper injection technique to prevent lipohypertrophy and dosing errors. - Consider cardiovascular status, as rapid glucose shifts can affect heart function.

Humulin Regular can interact with several medications, altering glucose control or increasing adverse event risk.

Avoid: - Concurrent use with sulfonylureas or meglitinides without dose adjustment may cause severe hypoglycemia. - Beta‑blockers can mask hypoglycemia symptoms, making detection difficult.

Use with caution: - Concurrent corticosteroids may increase insulin requirements. - Thiazide diuretics can raise blood glucose levels, necessitating dose changes. - ACE inhibitors may enhance insulin sensitivity, potentially leading to hypoglycemia. - Alcohol intake can potentiate insulin’s glucose‑lowering effect and precipitate hypoglycemia. - Growth hormone therapy may antagonize insulin action, requiring higher doses. - Certain antipsychotics may affect glucose metabolism, warranting closer monitoring.